sign-web

Daiichi Sankyo rocked by further job losses

December 9, 2015
Manufacturing and Production Daiichi, Daiichi Sankyo

The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …

roche_claudia

New member appointed to Roche board of directors

December 9, 2015
Business Services Roche

The Roche board of directors has proposed Dr Claudia Süssmuth Dyckerhoff, currently senior partner at McKinsey & Company, for election …

mark_forbes_irving

Former Quintiles director joins IDEA Pharma as MD

December 9, 2015
Medical Communications, Sales and Marketing IDEA Pharma, Mark Forbes Irving

IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, the new managing director joins …

healthy-human-t-cell_credit_celgene-web

Researchers launch CAR-T cell therapy trial in head and neck cancer

December 9, 2015
Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D

A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …

Coartem dosing

Novartis reaches 300 million free antimalarial treatments

December 9, 2015
Manufacturing and Production, Research and Development Coartem, Novartis, antimalarial treatment, malaria, non-profit

Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …

Collaboration

The age of collaboration: why pharma companies now have to work together

December 9, 2015
Research and Development R&D, co-operation, collaboration, pharma

It seems 2015 may be remembered as the year of the mega merger; the year when all records were broken …

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015
Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

janssen_latest_logo_on_sign_closer

Strong cancer trial data for Janssen at ASH 2015

December 8, 2015
Research and Development Cancer, Janssen, darzalex, imbruvica, oncology

Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …

EMA inside

Sandoz announces biosimilar successes

December 8, 2015
Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim

Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …

Lilly_labs_2

Lilly pulls plug on basal insulin Peglispro

December 8, 2015
Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure

Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …

Amgen scientist

Pharma companies ‘among happiest places to work’

December 8, 2015
Manufacturing and Production Jobs, careers, employee satisfaction, pharma jobs, recruitment

Five pharmaceutical companies have placed in a top 50 of the happiest companies in America listing, based on reviews by …

Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

Keytruda image

MSD’s Keytruda shows promise in multiple myeloma

December 7, 2015
Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab

MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …

eczema_finger

Featured Market Report: Atopic Dermatitis (eczema) Forecast in 17 Major Markets

December 7, 2015
Manufacturing and Production, Research and Development Black Swan, eczema

Featured Market Report: Forecast Report on Atopic Dermatitis (eczema) in 17 Major Markets  Black Swan’s report on Atopic Dermatitis, also …

Pfizer CEO Ian Read

Five benefits and challenges of the Pfizer/Allergan mega-merger

December 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …

Merck image

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015
Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …

Justice department

Mylan receives court summons from US Department of Justice

December 7, 2015
Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena

The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …

Takeda reveals five-year Adcetris survival data

December 6, 2015
Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …

The Gateway to Local Adoption Series

Latest content